Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Affiliation auteurs!!!! Error affiliation !!!!
TitreRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Type de publicationJournal Article
Year of Publication2014
AuteursBeau-Faller M., Prim N., Ruppert A.-M, Nanni-Metellus I., Lacave R., Lacroix L., Escande F., Lizard S., Pretet J.-L, Rouquette I., de Cremoux P., Solassol J., de Fraipont F., Bieche I., Cayre A., Favre-Guillevin E., Tomasini P., Wislez M., Besse B., Legrain M., Voegeli A.-C, Baudrin L., Morin F., Zalcman G., Quoix E., Blons H., Cadranel J.
JournalANNALS OF ONCOLOGY
Volume25
Pagination126-131
Date PublishedJAN
Type of ArticleArticle
ISSN0923-7534
Mots-clésaxon 18 mutations, epidermal growth factor receptor mutations, exon 20 mutations, Non-small-cell lung cancer, tyrosine-kinase inhibitors
Résumé

{Background: There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. Patients and methods: EGFR axon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network. Results: Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41(4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (Cl) 12-241, worse in smokers than in non-smoker patients with cxon 20 mutations (12 versus 21 months; hazard ratio [HR] for death 0.27, 95% Cl 0.08-0.87
DOI10.1093/annonc/mdt418